Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK

Davies, Ann D. M.; Vardeva, K; Loze, Jean‐Yves; L’Italien, Gilbert; Sennfält, Karin; Baardewijk, M van

doi:10.1185/03007990802507547

Cited by 24 publications

(41 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, most of cost studies in this field often fail to link costs to outcomes of care, and they do not necessarily specify the cost of psychopharmacological drug use. In the face of recent doubts about the cost-effectiveness of second-generation antipsychotics informed by controversial findings from various trials and meta-analyses (Rosenheck, 2006;Rosenheck et al, 2006;Jones et al 2006;Davies et a.l. 2008;Zhu et al 2008;Carpenter & Buchanan 2008), quantitative data in this field are fundamental to the ongoing transformation of community care systems.…”

Section: Introductionmentioning

confidence: 99%

Cost of treatment of schizophrenia in six European countries

Salize

McCabe

Bullenkamp

et al. 2009

Schizophrenia Research

View full text Add to dashboard Cite

Background and aims:As part of a RCT in six European sites, the direct mental health care cost for 422 patients with schizophrenia was analysed according to how total, and medication costs differed across sites and which variables were likely to predict total or service-specific costs.Method: Service use was recorded continuously during a 12-month follow-up. Prescribed psychotropic medication was recorded at baseline and 12 months later. Service use data were transformed into EURO, log-transformed and analysed using linear regression models. Results:Although samples were homogeneous, large inter-site cost differences were found (annual means ranging from 2,958 € in Spain up to 36,978 € in Switzerland). Psychopharmacologic costs were much more constant across sites than costs for other services. Total costs were associated more with region or socio-demographic characteristics than with disorder related parameters. Conclusions:The findings confirm remarkable differences in direct costs of patients wit schizophrenia across Europe. However, the relative stability of medication costs suggests a need to analyse mechanisms that influence service specific costs for schizophrenia.

show abstract

Section: Introductionmentioning

confidence: 99%

Cost of treatment of schizophrenia in six European countries

Salize

McCabe

Bullenkamp

et al. 2009

Schizophrenia Research

View full text Add to dashboard Cite

show abstract

“…Although every day the number of studies using this technique increases, 13,22,23 we did not find any other study where the technique was applied to elicit the probabilities of delay regarding maternal mortality. Therefore, our results set a precedent for the use of the methodology in future studies related to this complex issue, as well as in other research topics for which information is not available due to lack of studies, to its high costs, or because information is difficult to reproduce owing to health or environmental risks.…”

Section: Discussionmentioning

confidence: 89%

Global risk of death due to delays in the care of pregnant women with obstetric complication in yucatan, Mexico

Rodríguez-Angulo¹,

Pech²,

Zapata-Vázquez³

2018

OGIJ

View full text Add to dashboard Cite

Background: Delays in care of obstetric emergency exist. Studies involving specialists in charge of treating obstetric emergencies to get to know their perceptions on the care of maternal complications are scarce. There is evidence on the importance of taking into account the opinion of specialists in the face of complex problems, where the necessary information is difficult to come by with classical statistical methods.Objective: To estimate the global risk of maternal death due to delays. Methods:Elicitation technique with a panel of experts was used to elicit probabilities of delays regarding the care of the pregnant women with obstetric complications by means of Bayesian statistics. Four gyneco-obstetricians conformed the sample. Results:The global risk of maternal death due to delays was 54%. The final count of the global impact of mortality with the three-delay model in a real-life scenario was that 12.7% of the women with obstetric complication would die due to the presence of the three delays. Conclusion:The global risk of death for delays in obstetric emergency care, obtained from the GOs', should be taken into account for decision-makers, in order to promote strategies to prevent delays and thus contribute to the reduction of maternal mortality. Citation: Rodríguez-Angulo E, Pech GA, Vázquez RZ. Global risk of death due to delays in the care of pregnant women with obstetric complication in yucatan, Mexico.

show abstract

“…HPRL and EPS are assumed to remain for 3 months and diabetes and weight gain are assumed to be irreversible [31].…”

Section: Dosages Of Risperidonementioning

confidence: 99%

“…Unfortunately, this kind of study involving the use of a pharmacogenetic test does not exist to-date. Therefore, the patient stratification strategy was adapted using the data from Table 2 according to assumptions regarding the probabilities, which were based on published literature [31,32].…”

Section: Model Inputs Probabilitiesmentioning

confidence: 99%